NeuroMab™ Anti-Tau Antibody(NRP-0422-P1763)

Figure 1 shows the abbreviated tau for antibodies at 1:1000, 1:3000, 1:9000, 1:27000 and 1:81000 antibody dilutions. Immunospecificity for the Asp421 epitope is shown.

Figure 2 shows mixed cortical cultures of JNPL3 mice pretreated with PHF (1 μg/ml) against antibody 5G2A3 and antibody 1G11A10 (10 μg/ml) over time.

Figure 3 shows mixed cortical cultures of JNPL3 mice pretreated with PHF (1 μg/ml) against antibody 5G2A3 and antibody 1G11A10 (10 μg/ml) over time.

Figure 4 Effect of immunospecific binding of antibody to truncated tau Asp421 epitope.

Figure 5 Significant reductions in Iba1 levels were observed at 72 and 96 h in mixed cortical cultures treated with antibody 5G2A3 compared to cells treated with control and PHF only.

Figure 6 Effect of antibodies that can bind mixed neuronal cultures.

Figure 7 Co-incubation of antibody 1G11A10 antibody with PHF failed to demonstrate any significant changes in phospho-tau levels compared to cells treated with PHF alone and PHF + IgG at all time points.

Figure 8 Among antibodies 5G2A3 and 1G11A10, only antibody 5G2A3 was found to effectively reduce total tau levels.

Figure 9 Co-incubation of antibody 5G2A3 with PHF did not reveal any significant change in Iba1 levels compared to untreated control cells, whereas a significant increase in Iba1 levels was observed in PHF only, PHF + IgG and cells treated with PHF + Antibody 1G11A10.